KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Payables (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Payables data on record, last reported at $10.9 million in Q4 2025.

  • For Q4 2025, Payables fell 32.66% year-over-year to $10.9 million; the TTM value through Dec 2025 reached $10.9 million, down 32.66%, while the annual FY2025 figure was $10.9 million, 32.66% down from the prior year.
  • Payables reached $10.9 million in Q4 2025 per ACAD's latest filing, down from $21.7 million in the prior quarter.
  • Across five years, Payables topped out at $21.7 million in Q3 2025 and bottomed at $6.9 million in Q4 2021.
  • Average Payables over 5 years is $14.5 million, with a median of $14.5 million recorded in 2022.
  • Peak YoY movement for Payables: soared 122.47% in 2021, then plummeted 32.66% in 2025.
  • A 5-year view of Payables shows it stood at $6.9 million in 2021, then surged by 85.37% to $12.7 million in 2022, then soared by 37.64% to $17.5 million in 2023, then decreased by 7.7% to $16.2 million in 2024, then plummeted by 32.66% to $10.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $10.9 million in Q4 2025, $21.7 million in Q3 2025, and $20.1 million in Q2 2025.